Oncolytics Biotech Inc. (ONCY)
-NasdaqCM | Prev Close: | 2.72 |
|---|
| Open: | N/A |
|---|
| Bid: | 2.42 x 100 |
|---|
| Ask: | 3.70 x 1000 |
|---|
| 1y Target Est: | 6.47 |
|---|
| Beta: | 2.2 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.60 - 4.93 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 393,692 |
|---|
| Market Cap: | 230.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- A New Cancer-Killing Virusat Motley Fool(Thu, May 23)
- Can Financial Innovation Unlock a Cure for Cancer?at Motley Fool(Wed, May 22)
- Oncolytics rises on melanoma study resultsAP(Wed, May 22)
- Oncolytics cancer drug meets mid-stage trial goal, shares riseat Reuters(Wed, May 22)
- BRIEF-Oncolytics Biotech U.S.-listed shares jump 10.3 percent premarketat Reuters(Wed, May 22)
- InPlay: Oncolytics Biotech meets primary endpoint for first stage of u.s. phase 2 metastatic melanoma trialBriefing.com(Wed, May 22)
- Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma TrialCNW Group(Wed, May 22)
- Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma TrialPR Newswire(Wed, May 22)
- Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care ConferenceCNW Group(Tue, May 14)
- Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care ConferencePR Newswire(Tue, May 14)
- Oncolytics Biotech's CEO Presents at 2013 Annual Meeting of Shareholders Conference (Transcript)at Seeking Alpha(Sat, May 11)
- Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of ShareholdersCNW Group(Fri, May 10)
- Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of ShareholdersPR Newswire(Fri, May 10)
- Oncolytics Biotech® Inc. Announces First Quarter 2013 ResultsCNW Group(Thu, May 9)
- Oncolytics Biotech® Inc. Announces First Quarter 2013 ResultsPR Newswire(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.33 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers.
View More 
0.08%